Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
February 6, 2026Cancer

Antibody–drug conjugate combinations take center stage in recent urothelial cancer advancements

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLeah Lawrence

Discussion

Loading...

Member takes

Overview

News section highlights advancements in cancer treatments showing improved outcomes, suggesting promising future therapies.

Key Points

  • To report recent advancements in urothelial cancer treatments, focusing on antibody-drug conjugate combinations and their outcomes.
  • Review of recent major cancer therapy advancements
  • Analysis of survival data from various treatment regimens
  • Comparison of antibody-drug conjugates with traditional chemotherapy
  • Overall survival nearly doubled with disitamab vedotin plus toripalimab compared to chemotherapy
  • Nine-year data shows sustained benefit of nivolumab in high-risk resected melanoma
  • Zanzalintinib plus atezolizumab was the first immunotherapy to show benefits in metastatic colorectal cancer.

Cite This Study

Leah Lawrence (2026) studied this question.

synapsesocial.com/papers/698586ad8f7c464f2300a678https://doi.org/10.1002/cncr.70233
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Antibody–drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis2024 · 2 citations
  2. 2Antibody Drug Conjugates in Urothelial Carcinoma: Current Evidence and Practice Considerations2026
  3. 3Top advances of the year: Bladder cancer.2025
  4. 4Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven2025
  5. 5The efficacy and safety of disitamab vedotin plus immunotherapy in locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.2026